Chime Biologics, a global CDMO focused on biologics, has announced a strategic cooperation agreement with Polpharma Biologics. The agreement covers the full development and manufacturing cycle of a biosimilar product intended for global markets. Under the partnership, Chime Biologics will
Chime Biologics has reaffirmed its commitment to Mabgeek in advancing MG-K10, a novel IL-4Rα-targeting antibody drug for atopic dermatitis and asthma, into Phase III clinical trials. This collaboration follows Mabgeek’s successful engagement with the U.S. Food and Drug Administration (FDA), paving the way
Chime Biologics, a CDMO specialising in biologics, has entered a strategic partnership with Waterstone Pharmaceuticals to provide integrated services for the global Antibody-Drug Conjugate (ADC) industry. The partnership aims to support ADC developers in conducting IND-enabling and clinical studies, utilising
Chime Biologics, a global CDMO, has announced a new partnership with MedPacto, a KOSDAQ-listed South Korean company focused on developing cancer therapeutics. This strategic collaboration aims to streamline Chemistry, Manufacturing, and Controls (CMC) process development for MedPacto’s preclinical drug candidates,
Arbele, a biopharmaceutical company focusing on cadherin-17 (CDH17), has announced strategic partnerships in precision oncology aimed at advancing immunotherapeutics. These collaborations, involving BioAI Health and Chime Biologics, are expected to enhance the development of bispecific T-cell engagers (TCEs) and antibody-drug
